Acquired resistance to sunitinib is not associated with rescue angiogenesis in 786-O renal cell carcinoma xenografts
Simon P Robinson 1 , Naveen S Vasudev 2 , and Andrew R Reynolds 2
Division of Radiotherapy & Imaging, The
Institute of Cancer Research, Sutton, Surrey, United
Breast Cancer Research Centre, The Institute of Cancer
Research, London, United Kingdom
The response of 786-O RCC xenografts to sunitinib was
investigated using susceptibility contrast MRI with
USPIO particles. Fractional blood volume (fBV) was
significantly reduced after 2 weeks daily treatment in
the absence of any change in tumour volume. This reduced
fBV was maintained in 786-O xenografts exhibiting
acquired resistance to sunitinib.
This abstract and the presentation materials are available to members only;
a login is required.